SAN RAMON, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced its participation in the following upcoming investor conferences:
2024 Wells Fargo Healthcare Conference
Wednesday, September 4, 2024, at 3:45 pm ET
Al White, President & Chief Executive Officer, will represent the Company in a fireside chat
Morgan Stanley Annual Global Healthcare Conference
Thursday, September 5, 2024, at 1:50 pm ET
Al White, President & Chief Executive Officer, will represent the Company in a fireside chat
A webcast of each session will be available to investors and other interested parties by accessing the CooperCompanies’ website at http://investor.coopercos.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies (“Cooper”) has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$67.40 |
| Daily Change: | 2.81 4.35 |
| Daily Volume: | 3,854,062 |
| Market Cap: | US$13.450B |
August 27, 2025 March 06, 2025 December 17, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
